Engineered tumor-associated antigen

Engineered tumor-associated antigens are artificially designed or modified forms of natural tumor-associated antigens (TAAs), either through synthetic biology or genetic engineering, for use as specific targets in cancer immunotherapy. They are not a single molecule but a conceptual class intended to enhance tumor specificity, immunogenicity, or presentation of antigens to the immune system. These engineered antigens are typically used in the design of engineered T cell therapies (such as TCR-T or CAR-T cells) or cancer vaccines, aiming to direct immune responses against cancer cells[1][3][5]. This approach attempts to improve upon the limitations of natural TAAs, such as variable expression and risk of targeting healthy tissues, though many therapeutic challenges and safety considerations remain[1][3].

Other names

engineered TAAsynthetic TAAmodified tumor-associated antigen

Immune recognition by engineered T cells (e.g., TCR-T or CAR-T cells engineered to target specific TAAs) Induction of T cell–mediated cytotoxicity against tumor cells presenting the engineered antigen